Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Literature DB >> 24728785

The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Samuel Ryu¹, John M Buatti, Ann Morris, Steven N Kalkanis, Timothy Charles Ryken, Jeffrey J Olson.

Abstract

QUESTION: Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiation and chemotherapy? TARGET POPULATION: These recommendations apply to adult patients with progressive glioblastoma after first line combined multimodality treatment with chemotherapy and radiation. RECOMMENDATIONS LEVEL III: When the target tumor is amenable for additional radiation, re-irradiation is recommended as it provides improved local tumor control, as measured by best imaging response. Such re-irradiation can take the form of conventional fractionation radiotherapy, fractionated radiosurgery, or single fraction radiosurgery. LEVEL III: Re-irradiation is recommended in order to maintain or improve a patient's neurological status and quality of life prior to any further tumor progression.

Entities: Chemical

Mesh：

Year: 2014 PMID： 24728785 DOI： 10.1007/s11060-013-1337-6

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

42 in total

1. Hyperfractionated reirradiation for malignant glioma.

Authors: C Neider; U Nestle; M Niewald; K Walter; K Schnabel
Journal: Front Radiat Ther Oncol Date: 1999

2. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.

Authors: C Nieder; U Nestle; R Ketter; H Kolles; S J Gentner; W I Steudel; K Schnabel
Journal: Radiat Oncol Investig Date: 1999

3. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel.

Authors: G Lederman; M Wronski; E Arbit; M Odaimi; S Wertheim; E Lombardi; M Wrzolek
Journal: Am J Clin Oncol Date: 2000-04 Impact factor: 2.339

4. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

Authors: K H Cho; W A Hall; B J Gerbi; P D Higgins; W A McGuire; H B Clark
Journal: Int J Radiat Oncol Biol Phys Date: 1999-12-01 Impact factor: 7.038

5. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma.

Authors: Antje Ernst-Stecken; Oliver Ganslandt; Ulrike Lambrecht; Rolf Sauer; Gerhard Grabenbauer
Journal: J Neurooncol Date: 2006-09-20 Impact factor: 4.130

6. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.

Authors: S F Shepherd; R W Laing; V P Cosgrove; A P Warrington; F Hines; S E Ashley; M Brada
Journal: Int J Radiat Oncol Biol Phys Date: 1997-01-15 Impact factor: 7.038

7. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

Authors: Anca L Grosu; Wolfgang A Weber; Martina Franz; Sibylle Stärk; Morand Piert; Reinhard Thamm; Hartmut Gumprecht; Markus Schwaiger; Michael Molls; Carsten Nieder
Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038

Review 8. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma.

Authors: Carsten Nieder; Sabrina T Astner; Minesh P Mehta; Anca L Grosu; Michael Molls
Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339

9. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.

Authors: Stephanie E Combs; Marc Bischof; Thomas Welzel; Holger Hof; Susanne Oertel; Jürgen Debus; Daniela Schulz-Ertner
Journal: J Neurooncol Date: 2008-05-07 Impact factor: 4.130

10. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544

25 in total

1. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).

Authors: Pierina Navarria; Giuseppe Minniti; Elena Clerici; Stefano Tomatis; Valentina Pinzi; Patrizia Ciammella; Marco Galaverni; Dante Amelio; Daniele Scartoni; Silvia Scoccianti; Marco Krengli; Laura Masini; Lorena Draghini; Ernesto Maranzano; Valentina Borzillo; Paolo Muto; Fabio Ferrarese; Laura Fariselli; Lorenzo Livi; Francesco Pasqualetti; Alba Fiorentino; Filippo Alongi; Michela Buglione di Monale; Stefano Magrini; Marta Scorsetti
Journal: J Neurooncol Date: 2018-12-04 Impact factor: 4.130

2. Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions.

Authors: Mark E Linskey; Jeffrey J Olson; Laura S Mitchell; Steven N Kalkanis
Journal: J Neurooncol Date: 2014-08-01 Impact factor: 4.130

3. Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.

Authors: A Baehr; D Trog; M Oertel; S Welsch; K Kröger; O Grauer; U Haverkamp; H T Eich
Journal: Strahlenther Onkol Date: 2020-02-03 Impact factor: 3.621

Review 4. Polymeric drug delivery for the treatment of glioblastoma.

Authors: Scott D Wait; Roshan S Prabhu; Stuart H Burri; Tyler G Atkins; Anthony L Asher
Journal: Neuro Oncol Date: 2015-03 Impact factor: 12.300

5. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.

Authors: J Attal; L Chaltiel; V Lubrano; J C Sol; C Lanaspeze; L Vieillevigne; I Latorzeff; E Cohen-Jonathan Moyal
Journal: J Neurooncol Date: 2017-12-22 Impact factor: 4.130

6. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Authors: Klaus Müller; Guido Henke; Sophie Pietschmann; Stefaan van Gool; Steven De Vleeschouwer; André O von Bueren; Inge Compter; Carsten Friedrich; Christiane Matuschek; Gunther Klautke; Rolf-Dieter Kortmann; Thomas Hundsberger; Brigitta G Baumert
Journal: J Neurooncol Date: 2015-06-13 Impact factor: 4.130

Review 10. An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.

Authors: Sophie Pietschmann; André O von Bueren; Guido Henke; Michael Josef Kerber; Rolf-Dieter Kortmann; Klaus Müller
Journal: J Neurooncol Date: 2014-08-27 Impact factor: 4.130